- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07711769
Nurse-led Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in University Students With Mild to Moderate Mental Health Problems
23 juli 2026 bijgewerkt door: Shengzhi Zhao, The University of Hong Kong
Nurse-led Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) in University Students With Mild to Moderate Mental Health Problems: a Pilot Randomized Controlled Trial
This study aims to evaluate the feasibility, acceptability, and potential effectiveness of a nurse-led digital cognitive behavioral therapy for insomnia (dCBT-I) via large language model based-chatbot among university students with mental health problems.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Gedetailleerde beschrijving
This is a two-arm, parallel pilot randomized controlled trial recruiting 100 university students in Hong Kong with mild to moderate symptoms of depression or anxiety who also screen positive for insomnia symptoms.
All participants will receive brief sleep health advice and a booklet providing behavioral guidance on lifestyle and environmental factors related to sleep and insomnia.
Participants in the intervention group will additionally receive 12 weeks of chatbot-delivered insomnia management intervention, including 2 weeks of daily sleep diary monitoring and 10 weeks of nurse-led instant messaging support grounded in cognitive behavioral therapy for insomnia (CBT-I).
The primary outcome is self-reported insomnia severity at 6-month follow-up.
Secondary outcomes include health-related quality of life, sleep related quality of life, sleep effort, pre-sleep arousal, anxiety and depression assessed at 3 and 6 months.
Analyses will be conducted on intention-to-treat basis.
Studietype
Ingrijpend
Inschrijving (Geschat)
100
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Shengzhi Zhao
- Telefoonnummer: +852 6561 4500
- E-mail: lubabezz@connect.hku.hk
Studie Contact Back-up
- Naam: Tsz Kiu Chan
- Telefoonnummer: +852 5506 4711
- E-mail: natctk1@hku.hk
Studie Locaties
-
-
-
Hong Kong, Hongkong
- School of Public Health, The University of Hong Kong, 18/F, Metro South Tower 1, 39 Wong Chuk Hang Road, Wong Chuk Hang, Hong Kong
-
Contact:
- Shengzhi Zhao
- Telefoonnummer: +852 6561 4500
- E-mail: lubabezz@connect.hku.hk
-
Hoofdonderzoeker:
- Shengzhi Zhao
-
Contact:
- Tsz Kiu Chan
- Telefoonnummer: +852 5506 4711
- E-mail: natctk1@hku.hk
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Students aged ≥ 18 years from 22 local higher education institutions (University or Colleges) listed in Education Bureau.
- Screening score indicating mild to moderate anxiety or depression, defined as a GAD-7 score of 5-14 and/or a PHQ-9 score of 5-14 at baseline.
- Screened positive for insomnia symptoms using the Sleep Condition Indicator (SCI) and meeting DSM-5 diagnostic criteria for insomnia disorder.
- Reporting a self-reported sleep efficiency of less than 85% over the past month.
- Able to communicate in Chinese.
Exclusion Criteria:
- Participants who self-reported diagnosis of epilepsy, schizophrenia, or bipolar disorder
- Participants who self-reported current suicidal ideation with intent or a suicide attempt within the past 2 months
- Participants who self-reported current receipt of psychological or behavioral treatment for insomnia from a health professional
- Participants who self-reported participation in an online or digital insomnia treatment programme at the time of enrolment.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Interventie groep
|
At baseline, both groups will receive a 1-on-1 brief sleep health advice developed using guidelines by U.S. Centers for Diseases Control and Prevention and a booklet providing behavioral guidance on lifestyle and environmental factors related to sleep and insomnia.
Following randomization, participants in the intervention group will complete a 2-week chatbot-based daily sleep diary.
Each morning (e.g., 8:00 am), participants will be prompted via Whatsapp message delivered by chatbot to report key sleep parameters from the previous night, including bedtime, wake time, sleep onset latency, number and duration of nocturnal awakenings, total sleep time, and perceived sleep quality.
The collected sleep diary data will be processed by the chatbot to generate tailored and personalized feedback, supporting individualized sleep recommendations and behavioral adjustments.
At the initiation of the intervention, participants will also complete a brief baseline questionnaire to establish personalized treatment goals related to sleep improvement.
Throughout the intervention period, participants will have continuous access to chatbot-delivered support, including adaptive guidance based on diary inputs, reinforcement of recommended sleep strategies, and progress
Participants in the intervention group will also receive cognitive behavioral therapy for insomnia (CBT-I) delivered via an LLM-based chatbot through WhatsApp over a 10-week period.
The intervention is fully automated and available 24/7, with underlying algorithms enabling the delivery of information, therapeutic support, and advice in a personalized and adaptive manner, informed by participants' ongoing inputs and interaction patterns.
The intervention will be structured into 20 chatbot-delivered instant messaging (2 pieces per week).
The therapeutic content is adapted from established CBT-I manuals and led by research nurse, incorporating evidence-based behavioral, cognitive, and educational components.
Behavioral strategies include sleep restriction, stimulus control, and relaxation techniques.
Cognitive components comprise paradoxical intention, cognitive restructuring, mindfulness-based techniques, positive imagery, and strategies for "putting the day to rest."
Educational compone
|
|
Actieve vergelijker: Controlegroep
|
At baseline, both groups will receive a 1-on-1 brief sleep health advice developed using guidelines by U.S. Centers for Diseases Control and Prevention and a booklet providing behavioral guidance on lifestyle and environmental factors related to sleep and insomnia.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Self-reported insomnia severity
Tijdsspanne: 6-month follow-up
|
Assessed using the Insomnia Severity Index (ISI).
The ISI is a 7-item self-report instrument that evaluates both nocturnal and daytime symptoms of insomnia, with total scores ranging from 0 to 28, higher scores indicate greater insomnia severity.
|
6-month follow-up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Health-related quality of life
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using 36-Item Short Form Health Survey [SF-36].
The SF-36 is a 36-item self-reported instrument that measures both Physical Component Scores and Mental Component Scores, with scores ranging from 0 to 100; higher scores indicate better health-related quality of life.
|
3- and 6-month follow-ups
|
|
Sleep-related quality of life
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using Glasgow Sleep Impact Index [GSII].
The GSII is a 7-item self-report instrument that evaluates the sleep-related quality of life, with total scores ranging from 0 to 28, higher scores indicate lower level of sleep-related quality of life.
|
3- and 6-month follow-ups
|
|
Depressive symptoms
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using Patient Health Questionnaire-9 [PHQ-9].
The PHQ-9 is a 9-item self-report instrument that evaluates frequency and severity of depressive symptoms, with total scores ranging from 0 to 27, higher scores indicate higher level of depression.
|
3- and 6-month follow-ups
|
|
Anxiety symptoms
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using Generalized Anxiety Disorder-7 [GAD-7].
The GAD-7 is a 7-item self-report instrument that evaluates the frequency and severity of anxious symptoms, with total scores ranging from 0 to 21, higher scores indicate higher level of anxiety.
|
3- and 6-month follow-ups
|
|
Sleep effort
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using Glasgow Sleep Effort Scale [GSES].
The GSES is a 7-item self-reported instrument, with scores ranging from 0 to 14, higher scores indicate greater sleep effort.
|
3- and 6-month follow-ups
|
|
Pre-sleep arousal
Tijdsspanne: 3- and 6-month follow-ups
|
Assessed using Pre-Sleep Arousal Scale [PSAS].
The PSAS is a 16-item self-reported instrument consists of two subscales (cognitive arousal and somatic arousal), with scores ranging from 8 to 40 on each subscale, higher scores indicate greater pre-sleep arousal.
|
3- and 6-month follow-ups
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recruitment rate
Tijdsspanne: Baseline
|
Defined as the number of participants divided by the number of eligible university students.
|
Baseline
|
|
Retention rate
Tijdsspanne: 3- and 6-month follow-ups
|
Defined as the number of participants who completed the follow-up divided by the number of participants.
|
3- and 6-month follow-ups
|
|
Engagement rate of the interventions
Tijdsspanne: 3- and 6-month follow-ups
|
Engagement rate will be determined by Instant message (IM) log.
At least 2 times response will be considered as engaged.
|
3- and 6-month follow-ups
|
|
Usability for the development of a full-scale trial
Tijdsspanne: 3- and 6-month follow-ups
|
We will use the 10-item System Usability Scale (SUS) to assess perceived effectiveness, efficiency, and satisfaction of the intervention.
The score of SUS ranges from 0 to 100 and 68 is the threshold to determine the usability for the development of a full-scale trial.
|
3- and 6-month follow-ups
|
|
Usability of the chatbot
Tijdsspanne: 3- and 6-month follow-ups
|
The usability of the chatbot (Cronbach's alpha: 0.90) is measured by the validated 15-item Bot Usability Scale (BUS).
|
3- and 6-month follow-ups
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Onderzoekers
- Hoofdonderzoeker: Shengzhi Zhao, The University of Hong Kong
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 september 2026
Primaire voltooiing (Geschat)
30 september 2027
Studie voltooiing (Geschat)
31 oktober 2027
Studieregistratiedata
Eerst ingediend
13 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
13 juli 2026
Eerst geplaatst (Werkelijk)
17 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
24 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
23 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- dCBT-I in University Students
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .